Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers

Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

Go to full article published by Targeted Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.